Zoetis Inc. (ZTS)
Zoetis Inc. (ZTS) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $83.78, down 0.72% on the day, which values the company at $34.04B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $83.78−0.72% today
- Market value
- $34.04B
- P/E ratio
- 14.2×last 12 months
- Forward P/E
- 13.1×
- Dividend yield
- 2.48%
- Funk Score
- 72/100
- Against its own history
- Well below its usual priceusual price $186.06
- 200-week average
- $150.9845% below
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Zoetis Inc. in more detail
ZTS trades at 14.2× its last twelve months' earnings, 13.1× next year's expected earnings, 3.6× sales. Measured against its own history, the price is 55% below what its usual multiples would imply ($186.06) — well below its usual price. It sits 45% below its 200-week average of $150.98.
Over the last five fiscal years Zoetis Inc. has compounded revenue 7.2% a year, earnings per share 12.0% a year, free cash flow 6.4% a year. Its Funk Score is 72 out of 100 (financial strength 6.8, profitability 9.3, growth 5.6, value 7.1, each out of 10).
In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Debt is growing faster than cash flow.
13 of the superinvestors tracked here hold ZTS, including Tweedy, Browne team (3.7% of the portfolio), Sequoia Fund team (2.4% of the portfolio), Bill Smead (2.3% of the portfolio).
Superinvestors holding ZTS
13 of the investors tracked here report a position in their latest 13F filing.
- Tweedy, Browne team Tweedy, Browne Company3.71% of portfolio · $45.6M · added · Q3 2026
- Sequoia Fund team Ruane, Cunniff & Goldfarb2.37% of portfolio · $145.9M · trimmed · Q3 2026
- Bill Smead Smead Capital Management2.35% of portfolio · $110.4M · added · Q3 2026
- Ron Muhlenkamp (founder) Muhlenkamp & Co1.94% of portfolio · $8M · new · Q3 2026
- Diamond Hill team Diamond Hill Capital Management1.71% of portfolio · $157.1M · trimmed · Q3 2026
- Christopher Davis Davis Advisors1.08% of portfolio · $249.3M · new · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners0.93% of portfolio · $134.7M · trimmed · Q3 2026
- Mairs & Power team Mairs & Power0.46% of portfolio · $49.8M · added · Q3 2026
- Sarah Ketterer Causeway Capital Management0.44% of portfolio · $39.3M · new · Q3 2026
- Tom Gayner Markel Group0.23% of portfolio · $29.7M · added · Q3 2026
- Louis Bacon Moore Capital Management0.22% of portfolio · $7.9M · trimmed · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.16% of portfolio · $116M · added · Q3 2026
- Matthew McLennan First Eagle Investment Management0.08% of portfolio · $50.7M · new · Q3 2026
Health Care companies of similar size
- BiogenBIIB
- GE HealthCare TechnologiesGEHC
- AlconALC
- Mettler-Toledo InternationalMTD
- CenteneCNC
- GenmabGMAB
- IlluminaILMN
- ResMedRMD
- Labcorp HoldingsLH
- DexComDXCM
- Koninklijke PhilipsPHG
- Roivant SciencesROIV
Side by side:ZTS vs RMD (Zoetis Inc. vs ResMed)ZTS vs ILMN (Zoetis Inc. vs Illumina)ZTS vs GMAB (Zoetis Inc. vs Genmab)ZTS vs CNC (Zoetis Inc. vs Centene)ZTS vs MTD (Zoetis Inc. vs Mettler-Toledo International)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Zoetis Inc. (ZTS): questions and answers
What is ZTS's P/E ratio?
Zoetis Inc. trades at 14.2× its last twelve months' earnings and 13.1× next year's expected earnings. At its fiscal year-ends over the past 13 years the P/E ranged from 20.9× to 70.5×, with a median of 37.1×.
What is ZTS's PEG ratio?
Zoetis Inc.'s PEG ratio is 3.96 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Zoetis Inc.'s market cap?
Zoetis Inc. is valued at $34.04B at a share price of $83.78.
Is ZTS overvalued or undervalued?
Against its own history, ZTS is well below its usual price: the price is 55% below the $186.06 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ZTS above its 200-week moving average?
No. ZTS is 44.5% below its 200-week average of $150.98. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Zoetis Inc. growing?
Over the last five fiscal years Zoetis Inc.'s revenue grew 7.2% a year and its earnings per share 12.0% a year; over ten years revenue grew 7.1% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Zoetis Inc. (ZTS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ZTS
Underlying data: Yahoo Finance; company filings with the SEC.